2-((1r,4r)-4-methylcyclohexyl)acetic acid | 7132-93-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-((1r,4r)-4-methylcyclohexyl)acetic acid
• 英文别名: (trans-4-methyl-cyclohexyl)-acetic acid；(trans-4-Methyl-cyclohexyl)-essigsaeure；trans-4-Methyl-cyclohexyl-essigsaeure
• CAS: 7132-93-6
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: OQZGYMRYZAKXAF-ZKCHVHJHSA-N

物化性质

• 熔点：
  71.5-72.5 °C
• 沸点：
  106-108 °C(Press: 3.5 Torr)
• 密度：
  0.984±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.29
• 重原子数：
  11.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.3
• 氢给体数：
  1.0
• 氢受体数：
  1.0

安全信息

• 海关编码：
  2916209090

反应信息

• 作为反应物：
  描述：

  2-((1r,4r)-4-methylcyclohexyl)acetic acid 在 ammonium hydroxide 、 三氯化铝 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Carr; Gray; McDonnell, Molecular Crystals and Liquid Crystals (1969-1991), 1982, vol. 97, # 1-4, p. 13 - 28

  摘要：

  DOI：
• 作为产物：
  描述：

  ((1r,4r)-4-methylcyclohexyl)methanol 在 硫酸 、 氢溴酸 作用下， 以 溶剂黄146 、 二甲基亚砜 为溶剂， 生成 2-((1r,4r)-4-methylcyclohexyl)acetic acid
  参考文献：
  名称：

  Carr; Gray; McDonnell, Molecular Crystals and Liquid Crystals (1969-1991), 1982, vol. 97, # 1-4, p. 13 - 28

  摘要：

  DOI：

文献信息

• Über die Chiralität der enantiomeren 4-Methylcyclohexylidenessigsäuren
  作者：H. Gerlach

  DOI：10.1002/hlca.19660490412

  日期：——

  The chirality of the enantiomeric 4-methylcyclohexylideneacetic acids has been determined by a mechanistic correlation with (−)-isoborneol.

  对映体4-甲基环己叉基乙酸的手性已经通过与（-）-异冰片醇的机械相关性确定。
• BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS
  申请人：SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

  公开号：US20160096811A1

  公开（公告）日：2016-04-07

  Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D 3 receptor, 5-HT 1A receptor and 5-HT 2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.

  本发明涉及苯并异噻唑化合物及其在制备抗精神分裂症药物中的应用。本发明的苯并异噻唑化合物不仅具有与多巴胺D3受体、5-HT1A受体和5-HT2A受体的强亲和力，而且可以明显改善与阿泼吗啡模型和MK-801模型小鼠相关的精神分裂症症状，口服吸收良好，安全性高，副作用少，并具有作为新型抗神经症药物的开发价值。本发明是具有通式（I）结构的化合物，或其几何异构体、自由碱、盐、水合物或溶剂化物。
• [EN] FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS<br/>[FR] FURO[3,2-B]PYRROL-3-ONES EN TANT QU'INHIBITEURS DE CATHÉPSINE S
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2009112826A1

  公开（公告）日：2009-09-17

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl, C1-6-haloalkyl, C1-6- alkoxy, and C6-12-aralkyl; or R3 and R4 are each independently selected from C1-6-aIkyl and halo; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及式（I）的化合物，或其药学上可接受的盐，水合物，复合物或前药，其中：R3和R4中的一个为H，另一个选自C1-6烷基，C1-6卤代烷基，C1-6烷氧基和C6-12芳基烷基; 或R3和R4各自独立地选自C1-6烷基和卤素; R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-融合的双芳基或双杂芳基。式（I）的化合物表现出对人类卡特普辛S的惊人高效性，对其他哺乳动物卡特普辛具有优异的选择性，并可用于治疗风湿性关节炎，多发性硬化症，重症肌无力，移植排斥反应，糖尿病，Sjogrens综合症，Grave病，系统性红斑狼疮，骨关节炎，银屑病，特发性血小板减少性紫癜，过敏性鼻炎，哮喘，动脉粥样硬化，肥胖症，慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。
• CETP inhibitors
  申请人：Sakaki Junichi

  公开号：US20090075968A1

  公开（公告）日：2009-03-19

  The present invention relates to a compound of formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined.

  本发明涉及一种化合物的公式或其药学上可接受的盐，其中变量的定义如下。
• FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS
  申请人：AMURA THERAPEUTICS LIMITED

  公开号：US20130150345A1

  公开（公告）日：2013-06-13

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R 3 and R 4 is H, and the other is selected from C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, and C 6-12 -aralkyl; or R 3 and R 4 are each independently selected from C 1-6 -alkyl and halo; R 9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.

  本发明的第一个方面涉及公式(I)的化合物，或其药学上可接受的盐、水合物、复合物或前药，其中：R3和R4中的一个为H，另一个选自C1-6-烷基、C1-6-卤代烷基、C1-6-烷氧基和C6-12-芳基烷基; 或R3和R4各自独立地选自C1-6-烷基和卤代基; R9是取代的5或6成员芳基或杂芳基或6,5-或6,6-螺合的双芳基或双杂芳基。公式(I)的化合物表现出对人类卡特普汀S的惊人高效性，对其他哺乳动物卡特普汀具有优异的选择性，并可用于治疗风湿性关节炎、多发性硬化症、重症肌无力、移植排斥、糖尿病、Sjogrens综合症、Grave's病、全身性红斑狼疮、骨关节炎、牛皮癣、特发性血小板减少性紫癜、过敏性鼻炎、哮喘、动脉粥样硬化、肥胖症、慢性阻塞性肺疾病和慢性疼痛等疾病的治疗。